A cross-sectional study of U.S. insurance claims found that buprenorphine initiation during a telehealth visit was associated with a 36% lower overdose rate than in person and that patients in the former group were more likely to refill their prescriptions.
12 Sep 2023
ACP Spotlight offers readers a look at ACP's current top priorities and initiatives, as well as highlights from our e-newsletter, ACP Internist Weekly.
1 Nov 2023
This may be due to the sensitivity of the screening instrument, compounded by the stigma of opioid use disorder; addressing the latter may increase the instrument's sensitivity, the authors suggest.
17 Oct 2023
The U.S. government no longer requires an X waiver to treat patients with buprenorphine for opioid use disorder.
1 Mar 2023
Patients whose urine drug screens in the three weeks after beginning treatment for opioid use disorder (OUD) were negative for opioids had a 13% risk of returning to opioid use compared with 85% for those with three weeks of opioid-positive or missing results.
10 Oct 2023
This month's issue addresses alcohol use and misuse, prescribing buprenorphine, and improving health care's response to future pandemics.
1 Mar 2023
Fewer than a quarter of surveyed primary care physicians expressed interest in treating patients with opioid use disorder, and only 11.8% were interested in obtaining a waiver to prescribe buprenorphine.
21 Apr 2020
ACP's Chief Advocacy Officer issues a challenge to members of the College to be more “purple” in their outlook in order to achieve goals as a team, even when they disagree.
1 Jul 2023
Over 24 weeks, extended-release naltrexone cost an average of $5,317 more than buprenorphine-naloxone, primarily because the former was more expensive and required a longer detoxification period.
18 Dec 2018
The Drug Enforcement Administration is requiring eight hours of training related to substance use disorder treatment, sending clinicians scurrying to their continuing education providers for help.
1 May 2023